Inflammation and metabolic changes in first episode psychosis: Preliminary results from a longitudinal study

Brain, Behavior, and Immunity

Volumn 49, Issue , 2015, Pages 25-29

  Russell, Alice ^a   Ciufolini, Simone ^a   Gardner Sood, Poonam ^a   Bonaccorso, Stefania ^a   Gaughran, Fiona ^a   Dazzan, Paola ^a   Pariante, Carmine M ^a   Mondelli, Valeria ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

C reactive protein; Cholesterol; Dyslipidaemia; Glucose; Glycated haemoglobin; Inflammation; Insulin; Metabolic; Psychosis; Triglycerides

Indexed keywords

C REACTIVE PROTEIN; CHOLESTEROL; GLUCOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; INSULIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; BIOLOGICAL MARKER;

ADULT; AGED; ARTICLE; BODY MASS; BODY WEIGHT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CORRELATION ANALYSIS; FEMALE; GLUCOSE BLOOD LEVEL; HUMAN; INFLAMMATION; INSULIN BLOOD LEVEL; INSULIN RESISTANCE; LIPID ANALYSIS; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MULTIPLE LINEAR REGRESSION ANALYSIS; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PSYCHOSIS; TRIACYLGLYCEROL BLOOD LEVEL; UNITED KINGDOM; WEIGHT GAIN; ADOLESCENT; BIPOLAR DISORDER; BLOOD; METABOLISM; MIDDLE AGED; SCHIZOPHRENIA; YOUNG ADULT;

ADOLESCENT; ADULT; BIOMARKERS; BIPOLAR DISORDER; C-REACTIVE PROTEIN; FEMALE; HUMANS; INFLAMMATION; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; PSYCHOTIC DISORDERS; SCHIZOPHRENIA; TRIGLYCERIDES; YOUNG ADULT;

EID: 84940596436     PISSN: 08891591     EISSN: 10902139     Source Type: Journal    
DOI: 10.1016/j.bbi.2015.06.004     Document Type: Article

References (27)

1. Allison D.B., Mentore J.L., Heo M., Chandler L.P., Cappelleri J.C., Infante M.C., Weiden P.J. Antipsychotic-induced weight gain: a comprehensive research synthesis. Am. J. Psychiatry 1999, 156(11):1686-1696. Retrieved from .
2. Baumeister D., Russell A., Pariante C.M., Mondelli V. Inflammatory biomarker profiles of mental disorders and their relation to clinical, social and lifestyle factors. Soc. Psychiatry Psychiatr. Epidemiol. 2014, 49(6):841-849. 10.1007/s00127-014-0887-z.
3. Boyda H.N., Tse L., Procyshyn R.M., Honer W.G., Barr A.M. Preclinical models of antipsychotic drug-induced metabolic side effects. Trends Pharmacol. Sci. 2010, 31(10):484-497. 10.1016/j.tips.2010.07.002.
4. Brown S., Kim M., Mitchell C., Inskip H. Twenty-five year mortality of a community cohort with schizophrenia. Br. J. Psychiatry: J. Mental Sci. 2010, 196(2):116-121. 10.1192/bjp.bp.109.067512.
5. Correll C.U., Robinson D.G., Schooler N.R., Brunette M.F., Mueser K.T., Rosenheck R.A., Marcy P., Addington J., Estroff S.E., Robinson J., Penn D.L., Azrin S., Goldstein A., Severe J., Heinssen R., Kane J.M. Cardiometabolic risk in patients with first-episode schizophrenia spectrum disorders. JAMA Psychiatry 2014, 10.1001/jamapsychiatry.2014.1314.
6. Di Nicola M., Cattaneo A., Hepgul N., Di Forti M., Aitchison K.J., Janiri L., Murray R.M., Dazzan P., Pariante C.M., Mondelli V. Serum and gene expression profile of cytokines in first-episode psychosis. Brain Behav. Immun. 2013, 31:90-95. 10.1016/j.bbi.2012.06.010.
7. Duprez D.A., Somasundaram P.E., Sigurdsson G., Hoke L., Florea N., Cohn J.N. Relationship between C-reactive protein and arterial stiffness in an asymptomatic population. J. Hum. Hypertens. 2005, 19:515-519. 10.1038/sj.jhh.1001860.
8. Esteve E., Ricart W., Fernández-Real J.M. Dyslipidemia and inflammation: an evolutionary conserved mechanism. Clin. Nutr. 2005, 24(1):16-31. 10.1016/j.clnu.2004.08.004.
9. Hepgul N., Pariante C.M., Dipasquale S., DiForti M., Taylor H., Marques T.R., Morgan C., Dazzan P., Murray R.M., Mondelli V. Childhood maltreatment is associated with increased body mass index and increased C-reactive protein levels in first-episode psychosis patients. Psychol. Med. 2012, 42(9):1893-1901. 10.1017/S0033291711002947.
10. Hotamisligil G.S. Inflammation and metabolic disorders. Nature 2006, 444:860-867. 10.1038/nature05485.
11. Kay S.R., Fiszbein A., Opler L.A. The positive and negative syndrome scale (panss) for schizophrenia. Schizophr. Bull. 1987, 13(2):261-276. 10.1093/schbul/13.2.261.
12. Khovidhunkit W., Memon R.A., Feingold K.R., Grunfeld C. Infection and inflammation-induced proatherogenic changes of lipoproteins. J. Infect. Dis. 2000, 181(Suppl (Vldl)):S462-S472. 10.1086/315611.
13. Ladeia A.M., Stefanelli E., Ladeia-Frota C., Moreira A., Hiltner A., Adan L. Association between elevated serum C-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care 2006, 29(2):424-426. 10.2337/diacare.29.02.06.dc05-2033.
14. McGuffin P., Farmer A., Harvey I. Polydiagnostic application of operational criteria in studies of psychotic illness development and reliability of the OPCRIT system. Arch. Gen. Psychiatry 1991, 48(8):764-770. 10.1001/archpsyc.1991.01810320088015.
15. Miller B.J., Mellor A., Buckley P. Total and differential white blood cell counts, high-sensitivity C-reactive protein, and the metabolic syndrome in non-affective psychoses. Brain Behav. Immun. 2013, 31:82-89. 10.1016/j.bbi.2012.08.016.
16. Mitchell A.J., Vancampfort D., Sweers K., van Winkel R., Yu W., De Hert M. Prevalence of metabolic syndrome and metabolic abnormalities in schizophrenia and related disorders-a systematic review and meta-analysis. Schizophr. Bull. 2013, 39(2):306-318. 10.1093/schbul/sbr148.
17. Mondelli V., Anacker C., Vernon A.C., Cattaneo A., Natesan S., Modo M., Dazzan P., Kapur S., Pariante C.M. Haloperidol and olanzapine mediate metabolic abnormalities through different molecular pathways. Transl. Psychiatry 2013, 3(1):e208. 10.1038/tp.2012.138.
18. Mondelli V., Cattaneo A., Belvederi Murri M., Di Forti M., Handley R., Hepgul N., Miorelli A., Navari S., Papadopoulos A.S., Aitchison K.J., Morgan C., Murray R.M., Dazzan P., Pariante C.M. Stress and inflammation reduce brain-derived neurotrophic factor expression in first-episode psychosis: a pathway to smaller hippocampal volume. J. Clin. Psychiatry 2011, 72(12):1677-1684. 10.4088/JCP.10m06745.
19. Pearson T.A., Mensah G.A., Alexander R.W., Anderson J.L., Cannon R.O., Criqui M., Fadl Y.Y., Fortmann S.P., Hong Y., Myers G.L., Rifai N., Smith S.C., Taubert K., Tracy R.P., Vinicor F. Markers of inflammation and cardiovascular disease: application to clinical and public health practice: a statement for healthcare professionals from the Centers for Disease Control and Prevention and the American Heart Association. Circulation 2003, 107(3):499-511. 10.1161/01.CIR.0000052939.59093.45.
20. Potvin S., Stip E., Sepehry A.A., Gendron A., Bah R., Kouassi E. Inflammatory cytokine alterations in schizophrenia: a systematic quantitative review. Biol. Psychiatry 2008, 63(8):801-808. 10.1016/j.biopsych.2007.09.024.
21. Ramaswamy K., Masand P.S., Nasrallah H.A. Do certain atypical antipsychotics increase the risk of diabetes? A critical review of 17 pharmacoepidemiologic studies. Ann. Clin. Psychiatry 2006, 18(3):183-194. 10.1080/10401230600801234.
22. Ryan M.C.M., Collins P., Thakore J.H. Impaired fasting glucose tolerance in first-episode, drug-naive patients with schizophrenia. Am. J. Psychiatry 2003, 160(2):284-289. Retrieved from http://www.ncbi.nlm.nih.gov/pubmed/12562574.
23. Ryan M.C.M., Flanagan S., Kinsella U., Keeling F., Thakore J.H. The effects of atypical antipsychotics on visceral fat distribution in first episode, drug-naive patients with schizophrenia. Life Sci. 2004, 74(16):1999-2008. 10.1016/j.lfs.2003.08.044.
24. Song X., Fan X., Li X., Zhang W., Gao J., Zhao J., Harrington A., Ziedonis D., Lv L. Changes in pro-inflammatory cytokines and body weight during 6-month risperidone treatment in drug naïve, first-episode schizophrenia. Psychopharmacology 2014, 231(2):319-325. 10.1007/s00213-013-3382-4.
25. Taylor, D., Paton, C., Kapur, S., 2009. The Maudsley Prescribing Guidelines, 10th ed., Informa Healthcare. Doi:10.3109/9780203092835-2.
26. Woods S.W. Chlorpromazine equivalent doses for the newer atypical antipsychotics. J. Clin. Psychiatry 2003, 64(6):663-667. 10.4088/jcp.v64n0607.
27. World Health Organisation, 1992. The ICD-10 Classification of Mental and Behavioural Disorders: clinical descriptions and diagnostic guidelines. Geneva.